Precision BioSciences (NASDAQ:DTIL) Stock Rating Upgraded by Wall Street Zen

Precision BioSciences (NASDAQ:DTIL) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

DTIL has been the topic of several other reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Precision BioSciences in a research report on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of Precision BioSciences in a research note on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $39.50.

Precision BioSciences Stock Performance

NASDAQ:DTIL opened at $5.67 on Friday. The company’s 50 day moving average price is $4.18 and its 200-day moving average price is $4.99. Precision BioSciences has a 52 week low of $3.53 and a 52 week high of $8.82. The company has a quick ratio of 13.32, a current ratio of 13.32 and a debt-to-equity ratio of 0.24. The stock has a market cap of $140.22 million, a price-to-earnings ratio of -1.11 and a beta of 1.28.

Insider Transactions at Precision BioSciences

In other news, CEO Michael Amoroso sold 20,559 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total value of $78,946.56. Following the completion of the sale, the chief executive officer directly owned 243,392 shares in the company, valued at $934,625.28. This represents a 7.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO John Alexander Kelly sold 8,149 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total value of $31,292.16. Following the completion of the transaction, the chief financial officer directly owned 125,883 shares in the company, valued at approximately $483,390.72. This represents a 6.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 93,845 shares of company stock worth $376,677 in the last three months. Corporate insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in shares of Precision BioSciences by 5.5% during the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after acquiring an additional 4,025 shares during the period. Miller Financial Services LLC increased its holdings in Precision BioSciences by 50.0% in the 4th quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock worth $62,000 after acquiring an additional 5,000 shares in the last quarter. Lynx1 Capital Management LP raised its stake in Precision BioSciences by 0.6% during the 3rd quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock worth $5,755,000 after acquiring an additional 6,545 shares during the period. Quarry LP raised its stake in Precision BioSciences by 15.1% during the 4th quarter. Quarry LP now owns 68,311 shares of the company’s stock worth $284,000 after acquiring an additional 8,936 shares during the period. Finally, HBK Sorce Advisory LLC purchased a new position in Precision BioSciences during the fourth quarter valued at approximately $38,000. 37.99% of the stock is owned by hedge funds and other institutional investors.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.